SME Times is powered by   
Search News
Just in:   • Adani Group to invest Rs 57,575 crore in Odisha  • 'Dollar Distancing' finally happening? Time for India to pitch Rupee as credible alternative: SBI Ecowrap  • 49% Indian startups now from tier 2, 3 cities: Jitendra Singh  • 'India ranks 3rd in global startup ecosystem & number of unicorns'  • LinkedIn lays off entire global events marketing team: Report 
Last updated: 15 Feb, 2017  

pharmaTHMB.jpg Pharma pricing regulator cuts stent prices by up to 85 pc

india-pharma-industry.jpg
   Top Stories
» 49% Indian startups now from tier 2, 3 cities: Jitendra Singh
» 'India ranks 3rd in global startup ecosystem & number of unicorns'
» Tripura exported over 9K tonnes of pineapples in 2 years
» CPI inflation eases to 6.71% in July, IIP falls to 12.3%
» Rupee depreciates 12 paise to close at 79.64 against US dollar
SME Times News Bureau | 15 Feb, 2017
In a major measure of relief to cardiac patients in India, the government on Tuesday fixed the ceiling price of coronary stents which are used to open up blocked arteries.

The National Pharmaceutical Pricing Authority, in a notification, put a ceiling price on drug eluting stents (DES) and bioresorbable stents at Rs 29,600, and that of bare metal stents at Rs 7,260, effective from Tuesday. The ceiling price excludes local taxes.

The cost of a drug eluting stent currently ranges between Rs 24,000 and Rs 1.5 lakh, and that of a bioresorbable stent is between Rs 1.7 lakh to Rs 2 lakh. A bare metal stent costs between Rs 7,000 and Rs 20,000.

NPPA said it had consulted with various stakeholders on the matter.

"During deliberations, it was found that huge unethical markups are charged at each stage in the supply chain of coronary stents resulting in irrational, restrictive and exorbitant prices in a failed market system driven by information asymmetry between the patient and doctors pushing patients to financial misery," an NPPA notification said.

The NPPA also said that a stent could cost the patient over ten times more by the time it moved from the manufacturer to the patient.

In July 2016, the Union Health Ministry had, through a notification, included coronary stents under the National List of Essential Medicines (NLEM). Drugs and devices listed in the NLEM have to be sold at the price fixed by NPPA. This was after the Delhi High Court sought government action on a public interest litigation (PIL) appeal seeking price control on stents.
 
Print the Page Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
66.20
64.50
UK Pound
87.50
84.65
Euro
78.25
75.65
Japanese Yen 58.85 56.85
As on 13 Aug, 2022
  Daily Poll
PM Modi's recent US visit to redefine India-US bilateral relations
 Yes
 No
 Can't say
  Commented Stories
» GIC Re's revenue from obligatory cession threatened(1)
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter